Influence of impaired T‐ and B‐cell compartments on efficacy of IVIg in dysimmune neuropathies

Autoimmune mechanisms are postulated to play a role in the development and progression of dysimmune neuropathies (DN). We investigated the relation between lymphocyte number and marker expression, and disease activity in 20 patients with DN under intravenous immunoglobulins (IVIg) treatment. B‐ and T‐lymphocyte markers were studied by flow cytometry of the expression of CD5, CD25, CD23 and CD38 markers on B cells and of CD3, CD4 and CD8 markers, respectively. These parameters were compared with those obtained from matched healthy volunteers. The proportions of CD38+ B cells were higher in patients compared with those of controls. Proportions of activated CD4+ and CD8+ T cells were comparable in peripheral blood mononuclear cells of patients and controls, but a significant reduction of the absolute numbers of CD3+, CD4+ and CD8+ cells were observed in DN patients. The percentages of CD25+ memory T cells were instead significantly increased in DN patients. Lastly, T‐cell reduction and the CD19/CD38 ratio over total B (CD19+) cells directly correlated with a poor response to IVIg therapy. In DN, whereas T‐cell number is reduced, activated T and B cells are increased, thus suggesting an intrinsic defect of the immune response.

[1]  S. Piacentini,et al.  Long-term evolution of anti-ganglioside antibody levels in patient with chronic dysimmune neuropathy under IVIg therapy , 2006, Journal of Neuroimmunology.

[2]  Mei-Chih Huang,et al.  Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  R. Gold,et al.  Therapy of immune neuropathies with intravenous immunoglobulins , 2006, Journal of Neurology.

[4]  H. Shibasaki,et al.  CD16+CD57– Natural Killer Cells in Multifocal Motor Neuropathy , 2005, European Neurology.

[5]  E. Nobile‐Orazio,et al.  IVIg in idiopathic autoimmune neuropathies: analysis in the light of the latest results , 2005, Journal of Neurology.

[6]  P. Cardarelli,et al.  The receptor for type I IFNs is highly expressed on peripheral blood B cells and monocytes and mediates a distinct profile of differentiation and activation of these cells. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[7]  A. Ropper.  Current treatments for CIDP , 2003, Neurology.

[8]  R. Lewis,et al.  Consensus criteria for the diagnosis of multifocal motor neuropathy , 2003, Muscle & nerve.

[9]  B. Wolozin.  Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. , 2003, Archives of neurology.

[10]  M. Dalakas.  Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies , 2002, Neurology.

[11]  H. Willison,et al.  Peripheral neuropathies and anti-glycolipid antibodies. , 2002, Brain : a journal of neurology.

[12]  E. Breen.  Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. , 2002, Pharmacology & therapeutics.

[13]  V. Pascual,et al.  Increased Frequency of Pre-germinal Center B Cells and Plasma Cell Precursors in the Blood of Children with Systemic Lupus Erythematosus1 , 2001, The Journal of Immunology.

[14]  U. Dianzani,et al.  CD38 expression and functional activities are up‐regulated by IFN‐γ on human monocytes and monocytic cell lines , 2001, Journal of leukocyte biology.

[15]  L. H. van den Berg,et al.  Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. , 2000, Brain : a journal of neurology.

[16]  Sergio Romagnani,et al.  Macrophage-Derived Chemokine and EBI1-Ligand Chemokine Attract Human Thymocytes in Different Stage of Development and Are Produced by Distinct Subsets of Medullary Epithelial Cells: Possible Implications for Negative Selection1 , 2000, The Journal of Immunology.

[17]  R. Gold,et al.  Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. , 1999, Archives of neurology.

[18]  P. Limburg,et al.  Anti‐dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE) , 1996, Clinical and experimental immunology.

[19]  T. Logtenberg,et al.  Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases , 1995, Journal of Neuroimmunology.

[20]  J. Albers,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy , 1992, Neurology.

[21]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.